Picture a hospital ward during peak winter demand. Respiratory admissions are surging. The piped oxygen system serves the main wards, but in the treatment bays, the isolation rooms, and the ambulances pulling up outside, it is cylinders that keep patients breathing. When that supply is delayed, disrupted, or simply not there, the clinical consequences are immediate. Medical gas is not a commodity. It is a licensed medicine, a regulated product, and a patient safety dependency — and the NHS treats it accordingly.
The NHS SBS Medical and Industrial Gases framework SBS10526 launched in January 2026, replacing its predecessor SBS10040 after four years of operation. Just five suppliers hold places on it. If your organisation is one of them, the application process is behind you, but the work of winning contracts through the framework has only just begun. And if you are not yet on the framework, the four years between now and the 2030 renewal are not a waiting period. They are a preparation window.
SBS10526 is not simply a renewal of what came before. It represents a meaningful evolution in how NHS SBS approaches medical gas procurement. Understanding what has changed matters both for how suppliers position themselves in mini-competitions and for how they build towards the next renewal cycle.
The most significant structural change is the framework’s expanded scope. Where SBS10040 focused exclusively on NHS requirements, SBS10526 extends to industrial gases and wider public sector buyers. This includes fire and rescue services, educational institutions, and emergency services. That expansion opens a broader buyer base but also introduces a more diverse range of procurement needs, which suppliers need to reflect in how they present their capabilities across different lots.
Equally important is the procurement route. SBS10526 is the first NHS SBS medical gases framework procured under the Procurement Act 2023, which replaced the Public Contracts Regulations 2015 in October 2024. For suppliers, the Procurement Act introduces greater transparency obligations, more rigorous performance monitoring throughout the framework term, and a strengthened focus on value for money that goes beyond price. Bids written without awareness of this shift, particularly in how compliance and performance commitments are framed, may miss nuances that evaluators under the new regime will be looking for.
The new framework also introduces a dedicated sustainability lot for the first time, signalling a clear strategic direction.
SBS10526 is structured across four lots, each serving a distinct buyer need. Buyers access the framework either through a competitive mini-competition (the default route) or via direct award where conditions are met. In practice, most call-offs go through competition. Every mini-competition is, in effect, its own bid.
Lot 1: Medical gases in cylinders is the core lot for most suppliers on the framework. It covers oxygen, nitrous oxide, carbon dioxide, heliox, nitric oxide, and air/oxygen mixtures in cylinder form, alongside advanced cylinder tracking systems and the installation and maintenance of vacuum insulated evaporators (VIE) and backup facilities. For NHS buyers, this lot underpins continuity of care in every clinical setting that lacks piped gas. That covers everything from GP surgeries and dental practices to community hospitals and ambulance fleets.
Lot 2: Bulk liquid oxygen covers VIE tanks, backup facilities, rental and maintenance. This is the lot that serves large acute hospitals and specialist centres with high-volume, continuous oxygen requirements. Supply resilience and infrastructure capacity are the primary buyer concerns here.
Lot 3: Industrial gases is the new addition, bringing fire and rescue services, universities, and other wider public sector bodies within the framework’s reach. For suppliers with existing industrial gas capability, this lot represents a material expansion of addressable demand through a single compliant procurement vehicle.
<strong>Lot 4: Sustainable solutions covers technology, products and services that reduce the environmental impact of medical and industrial gas use. This includes nitrous oxide destruction units, one-touch digital cylinders with real-time usage data, and analgesic gas mixing and delivery systems. The inclusion of this lot is not incidental. It is a direct expression of the NHS’s commitment to cutting its anaesthetic gas carbon footprint by 40%, as set out in its net zero strategy.
Medical gases are classified as Medicines under the Medicines Act 1968. That classification determines the entire regulatory environment within which suppliers operate. An MHRA Manufacturer’s Specials Licence is required for the manufacture and supply of medical gases, and cylinder cleaning and disinfection must comply with MHRA DB 2006(05): Managing Medical Devices, covering the specific protocols for valves, regulators, and cylinder surfaces to prevent contamination.
In a mini-competition response, safety evidence is rarely the section that suppliers spend most time on. That is a mistake. NHS procurement teams evaluating medical gas contracts are acutely aware of the patient safety implications of supply failure. A response that simply lists licences held and certifications achieved will not score as well as one that demonstrates how the safety management system actually operates, particularly under pressure.
What does that look like in practice? It means:
These are not hypothetical scenarios for NHS buyers. They are operational realities, and responses that engage with them directly will consistently outscore those that do not.
Compliance in medical gas supply operates at multiple levels simultaneously, and evaluators expect suppliers to demonstrate fluency across all of them. Merely knowing that the requirements exist is not enough.
At the product level, British Compressed Gas Association (BCGA) Code of Practice compliance is mandatory for all framework suppliers. This covers everything from cylinder design and testing to filling, labelling, storage, and transport. The MHRA’s medical devices regulations govern the classification, traceability, and post-market surveillance of gas delivery equipment. These are non-negotiable baselines.
At the operational level, the Procurement Act 2023 introduces requirements that go beyond the PCR 2015 framework that governed SBS10040. Suppliers on NHS SBS frameworks are now subject to more rigorous performance monitoring and reporting obligations throughout the contract term, not just at award. The Act also places greater emphasis on how suppliers demonstrate ongoing compliance rather than point-in-time declarations. That shift affects how compliance evidence should be structured in both framework applications and mini-competition responses.
The most common compliance gap we see in this category is the difference between documentation that confirms status and documentation that demonstrates active management. A certificate of BCGA compliance tells an evaluator that you meet the standard at the point of assessment. A response that describes your internal audit schedule, your non-conformance management process, and your approach to keeping pace with regulatory updates tells them that you maintain that standard continuously and have the governance structures to prove it. The latter scores considerably better.
Of the three pillars, reliability is the most difficult to evidence convincingly. It is also the most persuasive when it is done well. It is the criterion that NHS buyers return to most consistently when making direct award decisions. A supplier who has demonstrated reliable performance over time, in comparable settings, has a qualitative advantage that no amount of well-written bid language can fully replicate.
The starting point is supply chain resilience. NHS evaluators want to understand your manufacturing capacity, your backup sourcing arrangements, and the geographic reach of your distribution network. Which clinical regions can you serve within what timeframes, and how does that change during high-demand periods?
Performance data from peak demand periods is particularly valuable here. If your organisation maintained service level compliance during the winter of 2022/23 (when respiratory admissions placed exceptional pressure on NHS oxygen supply chains) that is material evidence of reliability under realistic operating conditions. Highlight quantified performance data: delivery fulfilment rates, cylinder turnaround times, service level achievement against contract KPIs, customer satisfaction scores from NHS trusts. These are the building blocks of a compelling reliability case.
Digital infrastructure increasingly underpins reliability in medical gas supply. The one-touch digital cylinders available through Lot 4 provide real-time usage data that allows suppliers to anticipate demand and prevent stockouts before they become supply failures. If your organisation has invested in digital cylinder tracking and management systems, that capability is a reliability differentiator worth evidencing explicitly in your responses. Treat it not as a product feature, but as a demonstrated contribution to supply continuity for NHS patients.
Lot 4 exists because the NHS has a problem it urgently needs to solve. Anaesthetic gases, particularly nitrous oxide and the now largely phased-out desflurane, have an outsized environmental impact relative to their clinical volume. Nitrous oxide is a potent greenhouse gas, and its waste from anaesthetic delivery has been a significant contributor to the NHS’s carbon footprint. The net zero commitment to reduce anaesthetic gas emissions by 40% is not aspirational language. It has a delivery mechanism, and Lot 4 is part of it.
For suppliers across all four lots, sustainability is a scored quality criterion, not a supplementary section. The social value weighting on NHS SBS frameworks has grown consistently across successive procurement cycles. SBS10526, procured under the Procurement Act 2023, which explicitly strengthens the social value requirements on public contracts, is no exception. Responses that commit to measurable carbon reduction targets, responsible supply chain management, and local workforce development will score materially better than those that offer generic sustainability statements without specificity or accountability.
For suppliers on Lot 4, the opportunity is to position as a strategic partner in the NHS’s decarbonisation journey. That positioning, evidenced through deployment data, clinical adoption support, and outcome measurement, is what distinguishes the most competitive submissions in this lot from the rest.
SBS10526 runs until January 2030. For the five suppliers currently on the framework, those four years are both an opportunity and an obligation. The track record built through this framework term will be the most powerful evidence available when the renewal cycle opens. NHS case studies cannot be assembled at short notice ahead of a tender deadline. They are built continuously, contract by contract, over the life of the framework.
For suppliers not currently on SBS10526, the four-year horizon is genuinely useful preparation time. The compliance landscape will continue to evolve. The Procurement Act 2023 is still relatively new and its implications are still being worked through across the NHS supply chain. Building and maintaining BCGA compliance, MHRA licensing, and the sustainability credentials that Lot 4 demands is a multi-year investment. Engaging now with the bid strategy and positioning questions is the difference between a reactive scramble when the 2030 tender publishes and a well-prepared application that evaluators recognise immediately as the work of a serious, ready supplier.
At Bidding, we support medical and industrial gas suppliers with specialist bid writing. We translate genuine operational capability into responses that score at the top of the quality criteria. Our team understands the safety, compliance and reliability evidence standard that NHS evaluators apply in this category. What’s more, we know how to present it in the way that wins contracts. An independent bid review before any mini-competition submission is one of the highest-value steps you can take, ensuring that the evidence you have is working as hard as it can on the page.
With deep experience of NHS framework application support, Bidding is the partner that helps you turn framework membership into framework success. Get in touch and let’s talk about what your next submission needs to achieve.
Bidding Ltd © 2026
